Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

  


IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis
 

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT


The National Psoriasis Foundation
COVID-19 Task Force Guidance Statements

Twenty-five key recommendations for the management of patients with psoriatic disease during the COVID-19 pandemic.


READ STATEMENTS


THIS WEEKS' PUBLICATIONS ON COVID-19 & PSORIASIS

CONCLUSIONS: Systemic treatments for psoriasis (including biologics) were not associated with increased risk of in-hospital mortality due to COVID-19. These results support the maintain of systemic treatment for psoriasis during the pandemic.
Psoriasis is a chronic, immune-mediated inflammatory disease with heterogeneous clinical manifestations. Various trigger factors like infections and drugs are known to elicit or aggravate psoriasis. Previously, a possible association of vaccination and the new onset (particularly guttate lesions) or exacerbation of psoriasis has been reported.
No abstract
No abstract
Psoriasis is a chronic inflammatory skin disease that is characterized by well-demarcated erythematous plaques with a silver scale. Although many new and emerging therapeutic agents are often sufficient to control the disease, there is still a need for alternative treatment options in challenging cases. Extracorporeal photopheresis (ECP) has been applied to many T-cell-mediated diseases to restore immune homeostasis and treat psoriasis effectively. In this paper, we present a psoriasis patient...

VIEW ALL ON PUBMED

RECOURCES FROM OUR INDUSTRY PARTNERS

 AbbVie
Amgen
Novartis
UCB

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK